Key result
Study evaluates pivotal trial evidence quality for FDA priority review high-risk cardiovascular devices.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
This study uses publicly available FDA summaries to analyze the quality of evidence in pivotal studies that support cardiovascular premarket device approval under FDA priority review from 2007 to 2017.
No takes yet. Share an insight, caveat, or question.
Jones et al. (2018) studied this question. High-risk cardiovascular devices approved under the FDA priority review program from 2007 to 2017 were evaluated for the quality of clinical trial evidence in their pivotal studies.
Synapse has enriched 10 related papers. Consider them for comparative context: